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Abstract
Background Laparoscopic left lateral sectionectomy
(LLS) has gained popularity in its use for benign and
malignant tumors. This report describes the evolution of
the authors’ experience using laparoscopic LLS for dif-
ferent indications including living liver donation.
Methods Between January 2004 and January 2009, 37
consecutive patients underwent laparoscopic LLS for
benign, primary, and metastatic liver diseases, and for one
case of living liver donation. Resection of malignant
tumors was indicated for 19 (51%) of the 37 patients.
Results All but three patients (deceased due to metastatic
cancer disease) are alive and well after a median follow-up
period of 20 months (range, 8–46 months). Liver cell
adenomas (72%) were the main indication among benign
tumors, and colorectal liver metastases (84%) were the ﬁrst
indication of malignancy. One case of live liver donation
was performed. Whereas 16 patients (43%) had undergone
a previous abdominal surgery, 3 patients (8%) had LLS
combined with bowel resection. The median operation time
was of 195 min (range, 115–300 min), and the median
blood loss was of 50 ml (range, 0–500 ml). Mild to severe
steatosis was noted in 7 patients (19%) and aspeciﬁc portal
inﬂammation in 11 patients (30%). A median free margin
of 5 mm (range, 5–27 mm) was achieved for all cancer
patients. The overall recurrence rate for colorectal liver
metastases was of 44% (7 patients), but none recurred at
the surgical margin. No conversion to laparotomy was
recorded, and the overall morbidity rate was 8.1% (1 grade
1 and 2 grade 2 complications). The median hospital stay
was 6 days (range, 2–10 days).
Conclusions Laparoscopic LLS without portal clamping
can be performed safely for cases of benign and malignant
liver disease with minimal blood loss and overall morbid-
ity, free resection margins, and a favorable outcome. As the
ultimate step of the learning curve, laparoscopic LLS could
be routinely proposed, potentially increasing the donor
pool for living-related liver transplantation.
Keywords Laparoscopic liver surgery 
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The laparoscopic surgical approach to the liver has devel-
oped more slowly than laparoscopy used for other organs
due to several factors including the risk of bleeding, gas
embolism, doubts about the possibility of performing
oncologic resections, and the risks of cell seeding. Lack of
manual palpation (hand feedback), difﬁculty reproducing
the standard maneuvers, and the control of unattended
hemorrhage as in open surgery are the factors inﬂuencing
worldwide diffusion of a laparoscopic approach to the
liver. However, with the improvements in surgical instru-
mentation, many reports are describing a wide interest and
acceptance of this technique claimed to be feasible and safe
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DOI 10.1007/s00464-010-1133-8that yields decreased postoperative pain and disability,
reduces hospital stay, and shortens patient recovery time.
Since its ﬁrst successful description in 1996, left lateral
sectionectomy (LLS) is one of the most anatomic resec-
tions in liver surgery and probably the most standardized
laparoscopic approach to the liver [1–16]. Indeed, different
pathologies are currently treated with this technique.
In specialist centers, laparoscopic LLS is considered the
gold standard approach for lesions in segments 2 and 3.
It is proposed even for cirrhotic patients with portal
hypertension.
A look at the literature shows that the major laparo-
scopic LLS series are in most cases retrospective and case–
control studies. In these studies, the morbidity rate usually
ranges from 0% to 22%. The conversion rate ranges from
0% and 11% (with higher rates in early experiences), and
the mortality rate is approximately 0% (Table 1).
This study aimed to describe a single-center evolution of
laparoscopic LLS performed in recent years without portal
triad clamping and for different indications including live
liver donation for pediatric transplantation. Assessment of
morbidity and mortality, perioperative parameters, pathol-
ogy reporting, and outcome analysis, especially for meta-
static colorectal disease, are fully provided.
Patients and methods
Between January 2004 and January 2009, 622 liver resec-
tions were performed at the Ghent University Hospital. The
laparoscopic approach was used for 110 cases (17.7%).
Laparoscopic resection of Couinaud’s segments 2 and 3
(LLS) was performed for 37 (34%) of 110 patients. The
mean patient age was of 53 ± 15 years (range, 29–
77 years), and the male/female ratio was of 10/27. The
American Society of Anesthesiology (ASA) score was 1
for 20 patients, 2 for 12 patients, and 3 for 5 patients.
The indications for resection were benign solid liver
tumor (n = 17, 46%) and malignant tumor (n = 19, 54%)
for patients represented primarily by colorectal liver
metastases (CRLM). The evolution of the indication over
time is depicted in Fig. 1. Previous abdominal surgery or
liver resection was not considered an exclusion criterion
for the laparoscopic approach. The details are summarized
in Table 2. As the ultimate evolution of the surgical tech-
nique, we performed a laparoscopic living donor liver
resection in a young mother to provide a transplant for her
child with acute liver decompensation during the wait for a
deceased donor liver graft.
After approval of the local institutional review board, all
data were collected from a prospective liver resection
database. The variables considered were sex, age, ASA
score, indication for liver resection, histology of the native
liver, number and size of the nodules, free margins on the
cutting edge, operation time, blood loss, morbidity, and
hospital stay. Tumor pathology was assessed together with
the underlying liver tissue. Tumor-free margins, tumor
size, and percentage of cell necrosis were prospectively
recorded.
All procedures were performed under the direction of
the same attending surgeon (R.T.). The indication for
surgical treatment was determined during a multidisci-
plinary conference. The preoperative workup consisted of
ultrasound liver evaluation for 30 patients (81%), angiog-
raphy and computed tomography (CT) for 19 patients
(51%), magnetic resonance imaging (MRI) for 32 patients
(86%), and positron emission tomography (PET) and CT
for 18 patients (49%).
Surgical technique
Laparoscopic LLS was performed with the patient in
supine and 30 anti-Trendelenburg position, with the sur-
geon standing between the patient’s legs (French position).
Basically, four trocars (one 5 mm, one 10 mm, and two
12 mm trocars) were inserted in the upper abdominal
quadrant. Both 12-mm trocars were placed to allow
insertion of a 30 optical device and the linear stapler. The
10-mm trocar was inserted for the harmonic scissors or
surgical aspirator. The 5-mm (subxyphoidal) trocar was
placed to allow irrigation and aspiration during surgery,
and eventually to hang the liver when necessary (Fig. 2).
Carbon dioxide pneumoperitoneum was kept at about
10 mmHg. Assessment of the liver surface and surgical
margins were performed routinely under intraoperative
ultrasonographic guidance using the Aloka SSD 4000
(Aloka Co. Ltd., Tokyo, Japan). Laparoscopic LLS was
performed without preparation of the liver hilum for portal
triad clamping. The Harmonic scalpel (Ultracision; Ethicon
Endosurgery, Cincinnati OH, USA) and surgical aspirator
(CUSA Excel; Integra Life Science Ltd., IDA Business and
Technology Park, Ireland) were used for parenchymal
dissection (Fig. 3).
The operation started after dissection of eventual adhe-
sions in the upper abdominal quadrant. Division of the
round and falciform ligament toward the inferior vena cava
was seldom performed and only to allow careful intraop-
erative ultrasonography guidance for lesions near Rex’s
recessus or the left hepatic vein to assess surgical margins.
The left triangular ligament was freed before parenchymal
dissection was started, and the liver was transected on a
line just left of the falciform ligament. Manipulation of
tumoral lesions was systematically avoided in case of
malignancy, and no cholecystectomy was required.
Once the intrahepatic portal pedicles were visualized,
one or two vascular 45-mm linear staplers (EndoGIA;
80 Surg Endosc (2011) 25:79–87
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123Ethicon) were applied. The ﬁnal stage of the hepatectomy
was performed without exposure of the left hepatic vein,
which was stapled with a slim amount of surrounding
parenchyma to avoid unnecessary injury. Hemostasis was
performed through a combination technique including
bipolar cautery and an argon beamer coagulator. In a few
cases, titanium clips secured a hepatic vein draining a part
of segment 2 through the middle hepatic vein.
The surgical specimen was extracted through a Pfann-
enstiel incision or a previous laparotomy incision using a
plastic sterile bag. Drainage of the operative ﬁeld was
performed with a silastic drain (removed within 48–72 h)
in all cases.
For laparoscopic living liver donation, modiﬁcation of
the technique essentially involved dissection behind the
hilum to expose, free, and tape the left hepatic artery and
the left portal vein. Small branches going to the caudate
lobe were cut and secured by Hem-o-lock clips (TFX
Medical Ltd., RTP Durham, NC, USA) to maximize the
length of the left portal vein. When the dissection reached
the hilar plate, the left biliary duct was cut with a straight
scissors, and the proximal end was secured by a running
suture (PDS 5/0).
Fig. 1 Evolution of indications over time
Fig. 2 Positions of trocars in the upper abdominal quadrant
Fig. 3 Parenchyma dissection using the surgical aspirator (CUSA)
Table 2 Demographics and indication for left lateral sectionectomy
(LLS)
Demographic
Total no. 37
Male:female 10:27
Mean age (years) 53 ± 15
ASA score: 1, 2, 3 20, 12, 5
Previous abdominal surgery: n (%) 16 (43)
Combined bowel resection: n (%) 3 (8)
Laparoscopic LLS as repeat hepatectomy: n (%) 7 (19)
Indication for laparoscopic LLS
Benign: n (%) 18 (49)
Adenoma: n (%) 13 (72)
FNH 3
Hemangioma 1
Living liver donation 1
Malignant tumors: n (%) 19 (51)
CRLM: n (%) 16 (84)
HCC 1
GIST 1
Melanoma 1
ASA American Society of Anesthesiology, FNH focal nodular
hyperplasia, CRLM colorectal liver metastasis, HCC hepatocellular
carcinoma, GIST gastrointestinal stromal tumor
82 Surg Endosc (2011) 25:79–87
123After a Pfannestiel incision, a Gelport laparoscopic
system (Applied Medical, Rancho Santa Margarita, CA,
USA) was inserted to allow hand extraction of the graft.
When 5,000 U of heparin had been given intravenously, the
graft was procured as follows. With double Hem-o-lock
clips on both hepatic arteries (Endo TA, 30 mm; Tyco
Healthcare, Gosport PO130AS, UK) and on the left portal
vein, the EndoGIA (45 mm) was used to secure and cut the
left hepatic vein [17].
Statistical analysis
Results were expressed as median or mean ± standard
deviation. Student’s t-test, the chi-square test, and the
Mann–Whitney U test were used when appropriate. The
statistical signiﬁcance level was set at an alpha of 0.05.
Statistical analysis was performed using SPSS 15.0 for the
Windows program (SPSS, Chicago, IL, USA).
Results
The patient demographics and perioperative data are
summarized on Table 2. At this writing, all patients but
three are alive and well after a median follow-up period of
20 months (range, 8–46 months). Benign tumors were
represented primarily by liver cell adenomas, whereas
colorectal liver metastases (multiple in 36% of cases) were
the main indication for malignancy. A history of abdominal
surgery was recorded for 16 patients (43%), and
laparoscopic LLS was proposed as a repeat hepatectomy
for 7 patients (19%).
The overall median operation time (including anesthe-
sia) was 195 min (range, 115–300 min). However, for
three patients (8%) undergoing combined liver and bowel
resection, the operation time was, as expected, longer (300
vs. 185 min; p = 0.0001). The calculated median blood
loss was of 50 ml (range, 0–500 ml), and no transfusions
were required after surgery. Therefore, the results of the
learning curve comparing the ﬁrst 10 LLS procedures with
the remaining procedures (living donation excepted)
showed that the median operation time was statistically
shorter for the last 26 LLS procedures (232 vs 163 min;
p = 0.002). Similarly, there was a trend for decreased
blood loss in this group (150 ml; range, 0–350 ml vs.
50 ml; range, 0–500 ml; p = 0.109), but it did not reach
statistical signiﬁcance (Fig. 4).
The operative time was shown to be slightly longer for
malignancies (which became the ﬁrst indication for lapa-
roscopic LLS in the second part of our learning curve), and
the blood loss was signiﬁcantly less than with benign
tumors (Table 4). The Pfannenstiel incision was used for
26 patients (70%). Neither conversion to laparotomy nor
heterologous blood transfusion was recorded in this series.
Postoperative morbidity consisted of one grade 1 compli-
cation (postoperative ileus) and two grade 2 complications
(urinary tract infection and a germ-free hemorrhagic ﬂuid
collection drained percutaneously).
The median hospital stay was of 6 days (range,
2–10 days). However, this was longer for LLS procedures
Fig. 4 Effect of the learning curve according to operative time and blood loss in laparoscopic left lateral sectionectomy (LLS)
Surg Endosc (2011) 25:79–87 83
123combined with bowel resection (median stay, 8 days;
range, 7–10 days; p = 0.007) than for isolated LLS pro-
cedures (median stay, 5 days; range, 2–8 days).
The living liver donor successfully underwent the lap-
aroscopic donation without any adverse event. At this
writing, she is in excellent clinical condition.
Histology assessment
Final assessment showed that 2 of 13 liver cell adenomas
were focal nodular hyperplasia. The overall mean number
of lesions was 2 ± 1, and the mean lesion size was
55 ± 30 mm. However, benign resected nodules were
statistically larger than malignant resected nodules
(p = 0.01). The underlying liver parenchyma was found to
be normal in 13 patients (35%), steatotic in 7 patients
(19%; range, 5–60%), cirrhotic in 2 patients (5%), and
characterized by some degree of ﬁbrosis (F1–2) in 4
patients (10%) and by portal inﬂammation (A1-2) in
another 11 patients (30%). No toxicity related to chemo-
therapy was described. These details are listed in Table 3.
Cancer patients
Neoadjuvant chemotherapy (Folfox or Folﬁri plus bev-
acizumab) was administered to 8 (50%) of 16 patients with
CRLM, leading to 50% average cell necrosis. Malignant
lesions were resected with a minimal free margin of 5 mm
(median, 5 mm; range 5–27 mm). After a median follow-
up period of 21.5 months, two patients (12%) died of
tumoral disease progression (at 23 and 38 months of fol-
low-up evaluation, respectively), and seven patients (44%)
experienced relapse of their cancer. For six patients (37%),
CRLM led to a second hepatectomy, three of which
involved an iterative laparoscopic resection.
The overall survival rates were 87% at both 1 and
3 years. The disease-free survival was 81% at 1 year and
41% at 3 years. The patient with a metastatic uveal
melanoma experienced a relapse 3 months after LLS with
disseminated intrahepatic disease and died within the fol-
lowing 9 months. The patient with a gastrointestinal stro-
mal tumor (GIST) had a relapse under treatment with
tyrosine-kinase inhibitors (Glivec) and underwent a second
hepatectomy 30 months after the ﬁrst resection. At this
writing, no cancer at the level of the cutting edge, port
sites, or surgical incision have been observed.
Discussion
Since the publication of the ﬁrst nonanatomic liver resec-
tion and the ﬁrst left lateral lobectomy, laparoscopic liver
resection has been widely and increasingly performed for a
variety of benign and malignant diseases [18, 19]. The
development of this technique has been limited during this
time due to difﬁculty reproducing basic open liver surgery
maneuvers, risks of bleeding and pulmonary embolism, and
fear of compromising oncologic resection by tumoral cell
seeding [20, 21].
Laparoscopic LLS occupies a privileged position in lapa-
roscopic liver surgery since it gained rapid popularity (as
witnessed by several published series) for its well-deﬁned
anatomic surgical landmarks and relatively standardized
technique. The overall results from ﬁve published case-con-
trol studies and six retrospective case series show that LLS is
feasible and safe and that it is associated with low blood loss
and has no liver-speciﬁc morbidity [2–4, 10, 12, 13].
Out of 36 patients, a clear learning curve was demon-
strated in terms of operative time and use of the Pringle
maneuver, with hospital stay reduced by the last 18 patients
[10]. This also was observed in our series, conﬁrming that
this approach has an important teaching value, especially
for beginners in laparoscopic resectional surgery. The
Pringle maneuver actually is used in a minority of cases if
not abandoned altogether, even for cirrhotic patients, as
recently shown by other authors [22, 23]. Safe hemostasis
can be achieved with different hemostatic devices (e.g.,
clips, argon beamer, or vascular stapler).
We share the opinion of others that a careful dissection
of deep venous structures by the Harmonic scalpel or the
Cavitron Ultrasonic Surgical Aspirator (CUSA) is prefer-
able to avoid uncontrolled bleeding or pitfalls during liver
dissection [16]. However, limitation of bleeding during
dissection of cirrhotic patients probably could be better
achieved by the use of vascular staplers [22, 24]. In our
experience, there was a trend toward decreased bleeding
within the learning curve. However, we recorded signiﬁ-
cantly more blood loss with benign lesions than with
malignant tumors (Table 4, p = 0.01). This could be
explained not only as a learning curve effect but also by the
fact that severe steatosis was mostly predominant in benign
Table 3 Overall results
Median operative time: min (range) 195 (115–300)
a
Median blood loss: ml (range) 50 (0–500)
Conversion rate (%) 0
Transfusion rate (%) 0
Total morbidity rate: n (%) 3 (8.1)
Grade 1 1 (2.7)
Grade 2 2 (5.4)
Median hospital stay: days (range) 6 (2–10)
Median follow-up period (mos) 20 (8–46)
Overall mortality: n (%) 3 (8.1)
a Laparoscopic living donation not included
84 Surg Endosc (2011) 25:79–87
123solid tumors, which were the ﬁrst indication for laparo-
scopic LLS during the period 2004 to 2006 (Fig. 1).
Some series have reported an increase in postoperative
morbidity among patients with steatosis, particularly
infective complications and postoperative gastrointestinal
dysmotility [25, 26]. On the other hand, laparoscopic LLS
in the second group of procedures was performed almost
exclusively for patients with colorectal metastases and
neoadjuvant bevacizumab-based chemotherapy. Findings
have shown that this treatment can lead to an increase in
chemotherapy-associated steatosis and steatohepatitis
[27, 28]. Moreover, bevacizumab may enhance the risk of
bleeding, imposing an interval after the last administration
before liver resection is performed [29].
As our results show, we were not in a tight spot when
performing laparoscopic LLS for CRLM, as witnessed by
the signiﬁcantly decreased operative time and the identical
length of hospital stay (LOS) between the two groups,
conﬁrming the results of others [7]. In our experience, the
length of hospital stay did not change during this time.
However, for patients undergoing combined procedures
(bowel–liver resection), a statistically signiﬁcant LOS was
recorded (as intuitively expected), related primarily to
differences in intestinal transit time associated with the
healing of reconstructive colon surgery. Indeed, overall
complications were minimal, and no conversion to open
procedure was needed [5, 7, 12, 13]. Actually, LOS was
shorter than that recorded for open procedures and has
decreased as much as 3 to 5 days in the more recent series
compared with earlier experiences [12, 13].
Our acquired experience led us to propose laparoscopic
LLS also for patients with a history of hepatic resection for
CRLM. A total of 19 patients underwent laparoscopic LLS
asasecondhepatectomyforthisindicationofcancerrelapse,
whereas an iterative laparoscopic procedure was performed
for the remaining 3 patients. Adequate intraoperative tumor
assessment was provided by laparoscopy, resulting in free
margins conﬁrmed at the pathology report, without port-site
metastases at follow-up evaluation. Indeed, 81% and 41%
disease-free survivals at 1 and 3 years, respectively, after a
median follow-up of 20 months with a 44% recurrence rate
are in line with similar published experiences [6, 30].
The most recent data have shown that the oncologic
outcomes for selected patients undergoing laparoscopic
surgery are equivalent to those for open surgery [9, 12, 30,
31]. The use of biologic drugs (e.g., bevacizumab) did not
further increase bleedingin either open or laparoscopic liver
surgery [32, 33]. The favorable outcome we recorded for
iterative laparoscopic resection in a very few cases could
reﬂect some improvement in stress tolerance for repeated
hepatectomywhen the laparoscopic techniquewas used[31,
34]. The reduced overall morbidity observed with laparo-
scopic LLS is the main reason leading to the application of
this technique for live liver donation at experienced hepa-
tobiliary centers with the opportunity and knowledge to
perform pediatric or adult liver transplantation [8, 11].
Table 4 Comparison of
surgical outcomes and istology
assessment
CRLM colorectal liver
metastases, LLS left lateral
sectionectomy
a Laparoscopic living donation
not included
Benign
a Malignant p Value
Total no. 17 19
Median operative time: min (range) 182 (120–270) 215 (115–300) 0.39
Median blood loss: ml (range) 150 (0–500) 50 (0–350) 0.01
Median no. of tumoral nodules: n (range) 1.9 (1–5) 1.3 (1–3) 0.13
Resected tumor size: mm (range) 67.2 (12–114) 39.3 (17–80) 0.01
Median surgical margin: mm (range) – 5 (5–27) –
Underlying liver parenchyma: n (%)
Normal 5 (28) 8 (42) 0.23
Portal inﬂammation (A1–2): n (%) 4 (22) 7 (37)
Steatosis (5–60%): n (%) 5 (28) 2 (11)
Fibrosis (F1–2): n (%) 3 (17) 1 (5)
Cirrhosis: n (%) – 2 (10
Colorectal liver metastases
Median follow-up: mos (range) 22 (12–40)
Neoadjuvant treatment: n (%) 8 (50)
Mean percentage of cell necrosis in CRLM 50.6 ± 18.2
CRLM recurrence: n (%) 7 (44)
Median time to recurrence: mos (range) 12 (3–30)
First repeat hepatectomy after LLS: n (%) 6 (37)
Second repeat hepatectomy: n (%) 1 (6)
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123According to this published experience, the overall medical
complication rate was higher for open than for laparoscopic
procedures, with one retransplantation required in each of
the recipient groups.
No morbidity was recorded for our ﬁrst case in either the
donor or the recipient. Although no stronger evidence
exists that this technique is superior to the standardized live
donor resection, data available from new experiences cer-
tainly are encouraging, leading us to continue further on
this way [35]. Indeed, the difﬁculty obtaining randomized
controlled trials to prove the superiority of minimally
invasive techniques with respect to the standards is repre-
sented primarily by the small numbers of cases at each
center and the limited expertise in laparoscopic hepatob-
iliary surgery for pediatric and adult liver transplantation
groups. This is balanced by the possibility of overcoming
the pediatric organ shortage by increasing splitting liver
procedures [36].
Beyond the setting of laparoscopic live donation, the
major obstacle to showing signiﬁcant differences between
open and laparoscopic liver resection procedures is the
limited number of cases that can be randomized to an open
versus a laparoscopic approach as well as the small number
of experienced worldwide centers.
In conclusion, our experience reinforces the value of
laparoscopic LLS for different indications and demon-
strates that it can be performed safely with very low
morbidity, minimal blood loss, and a short hospital stay
for both normal and diseased liver parenchyma patients.
For cancer patients, radical resection could be achieved
with the potential to facilitate tolerance for a second
hepatectomy to manage cancer relapses (e.g., colorectal
metastases) during the follow-up period. The greatest
advantage of this surgical technique is indeed its repro-
ducibility and teaching value for hepatobiliary and lapa-
roscopic surgeons willing to approach laparoscopic liver
resection.
Laparoscopic LLS currently is considered primarily as a
laparoscopic procedure for cancer surgery performed in
very experienced centers for living donor hepatectomy
[8, 17, 35]. We think our case clearly pictures not only the
evolution of indications through our experience but also the
safety of this option and the needed expertise when it is
offered to healthy people such as living donors. In mean-
while, the future will teach us whether laparoscopic LLS
will become a routine approach for living donor liver
transplantation capable of reducing donor morbidity and
enhancing the donor organ pool.
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